Female gender and carcinoma in situ in the prostatic urethra are prognostic factors for recurrence, progression, and disease-specific mortality in T1G3 bladder cancer patients treated with bacillus Calmette-Guérin

European Urology

Volumn 62, Issue 1, 2012, Pages 118-125

  Palou, Joan ^a   Sylvester, Richard J ^b   Faba, Oscar Rodríguez ^a   Parada, Rubén ^a   Peña, Juan A ^a   Algaba, Ferran ^a   Villavicencio, Humberto ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b EORTC DATA CENTER   (Belgium)

Author keywords

Bacillus Calmette Gu rin; Bladder carcinoma; Disease progression; T1G3 urothelial cancer

Indexed keywords

BCG VACCINE;

ADULT; AGED; ARTICLE; BLADDER BIOPSY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CARCINOMA IN SITU; CONTROLLED STUDY; CYSTECTOMY; DEATH; DISEASE ASSOCIATION; DISEASE FREE INTERVAL; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NON MUSCLE INVASIVE BLADDER CANCER; PRIORITY JOURNAL; RECURRENT CANCER; RETROSPECTIVE STUDY; SEX DIFFERENCE; TRANSURETHRAL RESECTION; TUMOR VOLUME; URETHRA CARCINOMA;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; BCG VACCINE; CARCINOMA IN SITU; CYSTECTOMY; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROSTATE; RETROSPECTIVE STUDIES; SEX FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; URETHRA; URINARY BLADDER NEOPLASMS;

EID: 84861637633     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.10.029     Document Type: Article

References (28)

1. M. Babjuk, W. Oosterlinck, and R. Sylvester EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update Eur Urol 59 2011 997 1008
2. F. Millán-Rodríguez, G. Chéchile, J. Salvador, J. Palou, F. Algaba, and J. Vicente Primary superficial bladder cancer risk groups according to progression, mortality and recurrence J Urol 164 2000 680 684
3. J. Fernández-Gomez, E. Solsona, and M. Unda Club Urológico Español De Tratamiento Oncológico (CUETO). Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: multivariate analysis of data from four randomized CUETO trials Eur Urol 53 2008 992 1002
4. A. Orsola, I. Trias, and C.X. Raventós Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients Eur Urol 48 2005 231 238
5. D.L. Lamm, B.A. Blumenstein, and J.D. Crissman Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group study J Urol 163 2000 1124 1129
6. B.P. Schrier, M.P. Hollander, and B.W.G. van Rhijn Prognosis of muscle-invasive bladder cancer: difference between primary and progressive tumours and implications for therapy Eur Urol 45 2004 292 296
7. D.M. Kakiashvili, B.W. van Rhijn, and G. Trottier Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Gruèrin treatment BJU Int 107 2011 540 546
8. D. Denzinger, W. Otto, and H. Fritsche Bladder sparing approach for initial T1G3 bladder cancer: do multifocality, size of tumor or concomitant carcinoma in situ matter? A long-term analysis of 132 patients Int J Urol 14 2007 995 999
9. R.J. Sylvester, A.P.M. van der Meijden, and W. Oosterlinck Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials Eur Urol 49 2006 466 477
10. J. Fernandez-Gómez, R. Madero, and E. Solsona Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: the CUETO scoring model J Urol 182 2009 2195 2203
11. J. Fernandez-Gomez, R. Madero, E. Solsona Club Urológico Español de Tratamiento Oncológico (CUETO) The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables Eur Urol 60 2011 423 430
12. J.A. Witjes Bladder carcinoma in situ in 2003: state of the art Eur Urol 45 2004 142 146
13. G. Dalbagni, K. Vora, and M. Kaag Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer Eur Urol 56 2009 903 910
14. J. Palou, B. Xavier, P. Laguna, M. Montlleó, and J. Vicente In situ transitional cell carcinoma involvement of prostatic urethra: bacille Calmette-Guerin therapy without previous transurethral resection of the prostate Urology 47 1996 482 484
15. Redorta J. Palou, P. Schatteman, and Pérez J. Huguet Intravesical instillations with bacillus Calmette-Guérin for the treatment of carcinoma in situ involving prostatic ducts Eur Urol 49 2006 834 838
16. E. Solsona, I. Iborra, and J.V. Ricós The prostate involvement as prognostic factor in patients with superficial bladder tumors J Urol 154 1995 1710 1713
17. E. Solsona, I. Iborra, and J.V. Ricós Extravesical involvement in patients with bladder carcinoma in situ: biological and therapy implications J Urol 155 1996 895 899
18. N.A. Mungan, K.K.H. Aben, and M.P. Schoenberg Gender differences in stage-adjusted bladder cancer survival Urology 55 2000 876 880
19. J.C. Angulo, J.I. López, and D.J. Grignon Muscularis mucosa differentiates two populations with different prognosis in stage T1 bladder cancer Urology 45 1995 47 53
20. A. López-Beltrán, G. Sauter, and T. Gasser Infiltrating urothelial carcinoma J. Eble, G. Sauter, J. Epstein, WHO classification of tumours: pathology and genetics of the urinary system and male genital organs 2004 IARC Press Lyon, France 107 118
21. M. Takashi, K. Wakai, and T. Hattori Multivariate evaluation of factors affecting recurrence, progression, and survival in patients with superficial bladder cancer treated with intravesical bacillus Calmette-Guérin (Tokyo 172 strain) therapy: significance of concomitant carcinoma in situ Int Urol Nephrol 33 2002 41 47
22. T. Shinka, M. Matsumoto, H. Ogura, A. Hirano, and T. Ohkawa Recurrence of primary superficial bladder cancer treated with prophylactic intravesical Tokyo 172 bacillus Calmette-Guérin: a long-term follow-up Int J Urol 4 1997 139 143
23. H. Akaza, S. Hinotsu, Y. Aso, T. Kakizoe, and K. Koiso Bacillus Calmette-Guérin treatment of existing papillary bladder cancer and carcinoma in situ of the bladder: four-year results. The Bladder Cancer BCG Study Group Cancer 75 1995 552 559
24. E. Solsona, I. Iborra, and R. Dumont The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer J Urol 164 2000 685 689
25. H.W. Herr, and S.M. Donat Quality control in transurethral resection of bladder tumours BJU Int 102 2008 1242 1246
26. M. Miladi, M. Peyromaure, M. Zerbib, D. Saïghi, and B. Debré The value of a second transurethral resection in evaluating patients with bladder tumours Eur Urol 43 2003 241 245
27. M. Brausi, L. Colette, and K. Kurth Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies Eur Urol 41 2002 523 531
28. J. Palou, F. Algaba, I. Vera, O. Rodriguez, H. Villavicencio, and M. Sanchez-Carbayo Protein expression patterns of erzin are predictors of progression in T1G3 bladder tumours treated with nonmaintenance bacillus Calmette-Guerin Eur Urol 56 2009 829 836